Pompe Disease Market Pipeline H2 2015 Review and Comparative Analysis

Jan 22, 2016, 07:30 ET from ReportsnReports

PUNE, India, January 22, 2016 /PRNewswire/ --

ReportsnReports.com adds "Pompe Disease - Pipeline Review, H2 2015" market research report that provides an overview of the Pompe Disease's therapeutic with comprehensive information and comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects.

Complete report on H2 2015 pipeline review of Pompe Disease with 29 market data tables and 15 figures, spread across 81 pages is available at http://www.reportsnreports.com/reports/459942-pompe-disease-pipeline-review-h2-2015.html .

The report also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Pompe Disease - Pipeline Review, H2 2015 report include Alexion Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Audentes Therapeutics, Inc., BioMarin Pharmaceutical Inc., Cortex Pharmaceuticals, Inc., EpiVax, Inc., Etubics Corporation, Genzyme Corporation, greenovation Biotech GmbH, Oxyrane Belgium NV, Pharming Group N.V. and Sarepta Therapeutics, Inc. Drug Profiles mentioned in this report are Antisense Oligonucleotide to Activate Acid Alpha-Glucosidase for Pompe Disease, Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease, AT-002, ATB200 + Chaperone, CX-1739, CX-717, duvoglustat hydrochloride + alglucosidase alfa, Gene Therapy 1 to Activate Acid Alpha-Glucosidase for Pompe Disease, Gene Therapy to Activate Acid Alpha-Glucosidase for Pompe Disease, GZ-402666, MOSS-GAA, OXY-2810, Recombinant Enzyme to Replace Alpha Glucosidase for Pompe Disease, Recombinant Enzymes for Pompe, Fabry and Hunter Diseases, reveglucosidase alfa, Synthetic Peptides for Pompe disease and VAL-1221. Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=459942 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Pompe Disease and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities with key players involved in the therapeutics development for Pompe Disease and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, review of the Pompe Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Pompe Disease pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Another newly published market research titled Epidermolysis Bullosa - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Epidermolysis Bullosa Pipeline Review research report of 48 pages is available at http://www.reportsnreports.com/reports/459952-epidermolysis-bullosa-pipeline-review-h2-2015.html .

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:   http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com


SOURCE ReportsnReports